United States Últimas notícias

Consolidated Water (NASDAQ:CWCO), a provider of advanced water supply and treatment solutions, announced today that its board of directors has approved a quarterly cash dividend of $0.14 per share for the third quarter of 2026.

La Rosa Holdings (NASDAQ:LRHC) has released its financial results for the fiscal year ended December 31, 2025, reporting a 17% year-over-year increase in total revenue to $68.5 million.

Riyadh Air, Saudi Arabia's newest national carrier, has officially taken delivery of its first two factory-new Boeing 787-9 Dreamliners.

BioCardia (NASDAQ:BCDA) announced that minutes from a recent pre-submission (Q-Sub) meeting with the U.S. Food and Drug Administration (FDA) have provided a clearer regulatory roadmap for its CardiAMP Cell Therapy System.

Amneal Pharmaceuticals (NASDAQ:AMRX) has announced encouraging interim data from the Phase 4 ELEVATE-PD clinical trial, which evaluates the efficacy and safety of CREXONT (carbidopa and levodopa) extended-release capsules in patients living with Parkinson’s disease.

Hurco Companies (NASDAQ:HURC) announced its financial results for the second quarter of fiscal year 2026, showing significant momentum in booking activity and improved operational efficiency.

Argent Trust Company, acting as Trustee for the Sabine Royalty Trust (NYSE:SBR), has declared a cash distribution of $0.502990 per unit for June 2026.

Progress has stalled between the US and Iran in talks over an interim peace deal this week amid their worst clashes since an April ceasefire began and the continuation of fighting in Lebanon. Abeer Abu Omar reports on Bloomberg Television.

Lisa Shalett, CIO at Morgan Stanley Wealth Management, sees investors mistaking pricing power in semiconductors as productivity and says she views Broadcom as "a warning flag" for markets.

Embraer (NYSE:EMBJ) and aircraft lessor Azorra announced an expansion of their strategic partnership on June 5, 2026, with a new firm order for 15 E195-E2 aircraft.

Seres Therapeutics (NASDAQ:MCRB) announced a series of strategic financial moves aimed at strengthening its liquidity position.

Climb Bio (NASDAQ:CLYM) announced initial Phase 1 safety and pharmacokinetic data for its lead product candidate, CLYM116, at the 2026 European Renal Association (ERA) Congress in Glasgow.